Plain language summary
Alzheimer’s disease, which involves the most severe level of memory impairment, is mostly irreversible, thus it is critical to prevent deterioration of cognitive function. Spirulina is a microalga known to be high in nutrients and is considered one of the most perfect dietary supplements for humans because it contains many bioactive substances. The aim of this study was to report the effects of spirulina maxima 70% ethanol extract (SM70EE) on cognitive function in older adults (aged over 60 years) with memory impairment. This study is a randomised double-blind placebo-controlled trial. The study recruited eighty participants who were randomised into two equal-sized groups of 40 individuals each. The investigators and participants were blinded to the treatment regimens. Results showed statistically significant differences between the visual leading test and the visual working memory test. Furthermore, the vocabulary results showed a statistically significant difference between groups. SM70EE ingestion was determined to be safe for the human body because no clinically significant adverse reactions or physical changes were observed. Authors conclude that continuous intake of SM70EE could show improvement in memory function through improved visual memory and vocabulary.
Abstract
Spirulina maxima is a marine microalga that has been promoted worldwide as a super food. This study was conducted to evaluate its ability to improve memory in the older adults using Spirulina maxima 70% ethanol extract (SM70EE). This randomized, double-blind, placebo-controlled clinical trial comprised 80 volunteers recruited from Jeonbuk National University Hospital in Jeonju, Republic of Korea, who were randomly assigned to two groups. The participants received either 1 g/day of SM70EE or a placebo without otherwise changing their diet or physical activity. The participants were examined at baseline and after a 12-week interval to determine whether there were changes in their results for visual learning, visual working memory, and verbal learning tests from the Korean version of the Montreal Cognitive Assessment, brain-derived neurotrophic factor and beta-amyloid levels, and total antioxidant capacity. Compared to the placebo group, the treatment group showed a significant improvement in visual learning and visual working memory test results and enhanced vocabulary. SM70EE use was shown to improve memory, with no adverse effects. Its efficacy in alleviating Alzheimer's disease symptoms was verified for the first time through this clinical trial. SM70EE could play a role in the management of patients with dementia. This trial is registered with registration number of clinical research information service (CRIS: KCT0006161).
Methodological quality
Jadad score
:
5
Allocation concealment
:
Yes
